Aaron J. Bouchie | Jul 1, 2006 | 1 min read
Between 2003 and 2005, big pharma companies placed 52% more new drugs into clinical trials per year than in the prior five-year period, according to a study by the Tufts Center for the Study of Drug Development (CSDD). The CSDD included only new entities in clinical trials since 1993 (generics, new formulations of old drugs, or new indications for existing drugs were excluded), as determined according to total drug sales in 2004. The study addressed corporate merger activity by adding d